- The European Union has decided to take up an option under a supply contract with Moderna Inc MRNA that allows the bloc to order 150 million additional COVID-19 vaccines.
- This purchase brings the European Commission's confirmed order commitment to 460 million doses.
- The announcement comes a week after CureVac BV's CVAC COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's primary goal and casting doubt on the potential delivery of doses to the E.U.
- The additional doses will be delivered in 2022.
- The E.U. Commission said the second contract with Moderna had also been amended to allow the purchase of an updated variant booster vaccine candidate.
- Price Action: MRNA shares are up 3.34% at $215.21 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
